Overview
- Researchers at Vanderbilt and Stanford published a Nature Biotechnology paper that describes a single‑cell spatial pharmacobiology (SSP) platform that images how antibody therapeutics distribute and bind inside human solid tumors.
- The team applied SSP to head and neck, pancreatic and other tumor samples and found pronounced spatial heterogeneity in drug delivery and target engagement across and within tumors.
- Data in the paper, released Wednesday, point to dense stromal architecture—the noncancerous connective tissue around tumors—as a conserved physical barrier that limits antibody penetration into tumor regions.
- SSP can distinguish tumor areas that are underexposed to a drug from areas that are biologically unresponsive, a distinction that can change whether a failed therapy is blamed on delivery or on molecular resistance.
- The authors note the work was NIH‑funded and say larger, prospective patient cohorts are needed to validate SSP before it is used to guide trial design, therapeutic choices or fluorescence‑guided surgery decisions.